{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:40:01Z","timestamp":1787017201681,"version":"build-2736575974"},"reference-count":50,"publisher":"BMJ","issue":"15","funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["agreement #075-15-2020-800"],"award-info":[{"award-number":["agreement #075-15-2020-800"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Special Research Fund (BOF) of Hasselt University","award":["BOF19PD04"],"award-info":[{"award-number":["BOF19PD04"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2021,11,18]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Hyponatraemia is very common in heart failure (HF), especially in decompensated patients. It is associated with increased mortality and morbidity and considered a marker of advanced disease. Recognition of hyponatraemia and its causes may help guide treatment strategy. Historically, therapy has primarily focused on water restriction, decongestion with loop diuretics in case of volume overload (dilutional hyponatraemia) and sodium repletion in case of depletion. In this review, we summarise the potential benefits of established and emerging HF therapies on sodium homeostasis, with a focus on dual vasopressin antagonists, angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors and hypertonic saline, and propose a potential therapeutic approach for hyponatraemia in HF.<\/jats:p>","DOI":"10.1136\/heartjnl-2021-320277","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T13:20:28Z","timestamp":1639401628000},"page":"1179-1185","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Hyponatraemia in heart failure: time for new solutions?"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-3027","authenticated-orcid":false,"given":"Agnieszka","family":"Kap\u0142on-Cie\u015blicka","sequence":"first","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-0660","authenticated-orcid":false,"given":"Anzhela","family":"Soloveva","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Almazov National Medical Research Centre, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yura","family":"Mareev","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation"},{"name":"Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Cabac-Pogorevici","sequence":"additional","affiliation":[{"name":"Department of Cardiology, State University of Medicine and Pharmacy 'Nicolae Testemitanu', Chisinau, Moldova (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik Hendrik","family":"Verbrugge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium"},{"name":"Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Vardas","sequence":"additional","affiliation":[{"name":"Heart Sector, Hygeia Hospitals Groups, Athens, Greece"},{"name":"Medical School, Cardiology Department, University of Crete, Heraclion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"2025092002114742000_108.15.1179.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl542"},{"key":"2025092002114742000_108.15.1179.2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.20452\/pamw.2701","article-title":"Clinical characteristics and 1-year outcome of hyponatremic patients hospitalized for heart failure","volume":"125","author":"Kap\u0142on-Cie\u015blicka","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"2025092002114742000_108.15.1179.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2013.04.001"},{"key":"2025092002114742000_108.15.1179.4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/imj.14624","article-title":"Hyponatraemia in heart failure","volume":"50","author":"Tee","year":"2020","journal-title":"Intern Med J"},{"key":"2025092002114742000_108.15.1179.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.03.017"},{"key":"2025092002114742000_108.15.1179.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.584102"},{"key":"2025092002114742000_108.15.1179.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1319"},{"key":"2025092002114742000_108.15.1179.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.12.010"},{"key":"2025092002114742000_108.15.1179.9","doi-asserted-by":"publisher","DOI":"10.14740\/cr553w"},{"key":"2025092002114742000_108.15.1179.10","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-0368"},{"key":"2025092002114742000_108.15.1179.11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.12","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu307"},{"key":"2025092002114742000_108.15.1179.13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/jcm8030349","article-title":"Acetazolamide therapy in patients with heart failure: a meta-analysis","volume":"8","author":"Wongboonsin","year":"2019","journal-title":"J Clin Med"},{"key":"2025092002114742000_108.15.1179.14","first-page":"1032","article-title":"Treatment of Hyponatremia with Acetazolamide in Cardiovascular patients:Possible Alternative Diuretic to Vasopressin Antagonists","volume":"3","author":"Kataoka","year":"2020","journal-title":"Ann Cardiol Vasc Med"},{"key":"2025092002114742000_108.15.1179.15","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ejhf.1307","article-title":"Rationale and design of the ADVOR (acetazolamide in decompensated heart failure with volume overload) trial","volume":"20","author":"Mullens","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.16","doi-asserted-by":"crossref","DOI":"10.1177\/1753944720977741","article-title":"Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials","volume":"15","author":"Urbach","year":"2021","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2025092002114742000_108.15.1179.17","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.614","article-title":"Tolvaptan add-on therapy in patients with acute heart failure: a systematic review and meta-analysis","volume":"8","author":"Luo","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"2025092002114742000_108.15.1179.18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ejhf.2001","article-title":"Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a\/V2 receptor antagonist in experimental heart failure","volume":"23","author":"Mondritzki","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7150\/ijbs.20074","article-title":"Vasopressin mediates the renal damage induced by limited fructose rehydration in recurrently dehydrated rats","volume":"13","author":"Garc\u00eda-Arroyo","year":"2017","journal-title":"Int J Biol Sci"},{"key":"2025092002114742000_108.15.1179.20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cardfail.2020.10.007","article-title":"Dual vasopressin receptor antagonism to improve congestion in patients with acute heart failure: design of the AVANTI trial","volume":"27","author":"Goldsmith","year":"2021","journal-title":"J Card Fail"},{"key":"2025092002114742000_108.15.1179.21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.0954-6820.1986.tb18123.x","article-title":"Effects of ACE inhibition on renal regulation of salt and water","volume":"707","author":"Gr\u00f6nhagen-Riska","year":"1986","journal-title":"Acta Med Scand Suppl"},{"key":"2025092002114742000_108.15.1179.22","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/00005344-199219006-00008","article-title":"Renal prostaglandin synthesis and angiotensin-converting enzyme inhibition","volume":"19 Suppl 6","author":"Wilson","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025092002114742000_108.15.1179.23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.35"},{"key":"2025092002114742000_108.15.1179.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(01)00248-6"},{"key":"2025092002114742000_108.15.1179.25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of Sacubitril-Valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2025092002114742000_108.15.1179.26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","article-title":"Effects of Sacubitril\/Valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension","volume":"69","author":"Wang","year":"2017","journal-title":"Hypertension"},{"key":"2025092002114742000_108.15.1179.28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092002114742000_108.15.1179.29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/0897190019828915","article-title":"Sacubitril\/Valsartan (Entresto\u00ae)-Induced Hyponatremia","volume":"33","author":"Fuzaylova","year":"2020","journal-title":"J Pharm Pract"},{"key":"2025092002114742000_108.15.1179.30","article-title":"Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report","author":"Mohammed","year":"2020","journal-title":"Postgrad Med J"},{"key":"2025092002114742000_108.15.1179.31","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2459\/JCM.0000000000001018","article-title":"Sacubitril\/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction","volume":"21","author":"Mapelli","year":"2020","journal-title":"J Cardiovasc Med"},{"key":"2025092002114742000_108.15.1179.32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2025092002114742000_108.15.1179.33","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11739-019-02111-6","article-title":"Renal effects of Sacubitril\/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study","volume":"14","author":"Spannella","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2025092002114742000_108.15.1179.34","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"2025092002114742000_108.15.1179.35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"2025092002114742000_108.15.1179.36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045691"},{"key":"2025092002114742000_108.15.1179.37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind red trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"2025092002114742000_108.15.1179.38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.40","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019090944"},{"key":"2025092002114742000_108.15.1179.41","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31820f10ad"},{"key":"2025092002114742000_108.15.1179.42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijcard.2011.11.087","article-title":"Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure","volume":"167","author":"Issa","year":"2013","journal-title":"Int J Cardiol"},{"key":"2025092002114742000_108.15.1179.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2011.09.006"},{"key":"2025092002114742000_108.15.1179.44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00059-013-4041-6","article-title":"Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: a meta-analysis of the literature","volume":"40","author":"De Vecchis","year":"2015","journal-title":"Herz"},{"key":"2025092002114742000_108.15.1179.45","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11897-019-00444-z","article-title":"Utility of urine biomarkers and electrolytes for the management of heart failure","volume":"16","author":"Verbrugge","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"2025092002114742000_108.15.1179.46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025092002114742000_108.15.1179.47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001377"},{"key":"2025092002114742000_108.15.1179.48","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"2025092002114742000_108.15.1179.49","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025092002114742000_108.15.1179.50","doi-asserted-by":"crossref","unstructured":"Martens P , Ferreira JP , Vincent J , et al . Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial. Clin Res Cardiol;11.doi:10.1007\/s00392-021-01853-8","DOI":"10.1007\/s00392-021-01853-8"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2021-320277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:11:56Z","timestamp":1758359516000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2021-320277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":50,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,7,13]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/heartjnl-2021-320277"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2021-320277","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}